Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced? Hoivik ML. Lancet Gastroenterol Hepatol 2025 Oct 27:S2468-1253(25)00258.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hoivik ML. Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced? Lancet Gastroenterol Hepatol 2025 Oct 27:S2468-1253(25)00258.
PMID: 41167234